{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.85","upperLimit":"7.87","value":"5.420"},{"groupId":"OG001","lowerLimit":"1.83","upperLimit":"13.50","value":"13.350"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"30.8","value":"8.91"},{"groupId":"OG001","lowerLimit":"18.1","upperLimit":"19.5","value":"18.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.9","upperLimit":"26.9","value":"26.90"},{"groupId":"OG001","lowerLimit":"23.9","upperLimit":"66.2","value":"45.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.4","upperLimit":"18.4","value":"18.40"},{"groupId":"OG001","lowerLimit":"21.7","upperLimit":"21.7","value":"21.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Cycle 10"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.0","upperLimit":"18.1","value":"18.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Cycle 13"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. Ctrough was calculated as the observed concentration at the end of a dosing interval, immediately before next study drug administration on Day 1 of each Cycle. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Full Range","groups":[{"description":"Participants were administered 2.5 mg/kg of belantamab mafodotin in combination with 200 mg of pembrolizumab via intravenous (IV) infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal , or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation"},{"description":"Participants were administered 3.4 mg/kg of belantamab mafodotin in combination with 200 mg of pembrolizumab via intravenous (IV) infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal , or for a maximum of 35 cycles.","id":"OG001","title":"Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Cycle 4, Cycle 7, Cycle 10, and Cycle 13","title":"Part 1 - Ctrough for Total mAb","type":"SECONDARY","unitOfMeasure":"ug/mL"}